An observational study in Urothelial Carcinoma, Non-Small Cell Lung Cancer and Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 257 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Hoffmann-La Roche · Observational
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.
The study will be split into separate cohorts based on the approved indications for atezolizumab treatment, excluding cisplatin ineligible participants receiving atezolizumab as first line of therapy (LOT1) for locally advanced/metastatic urothelial cancer (locally advanced/metastatic UC). The study may be amended for inclusion of new cohorts as these are approved in the participating countries. Participants will be included into each cohort based on their indication for receiving atezolizumab.
633 studies on the registry are indexed under Carcinoma, Transitional Cell; 181 are open to participants now.
This study's enrollment of 2,756 is above the median of 300 across 107 observational studies indexed under Carcinoma, Transitional Cell.
Browse Carcinoma, Transitional Cell studies →Hoffmann-La Roche is the lead sponsor of 2,101 studies on the registry; 87 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants diagnosed with locally advanced /mUC previously treated with platinum-containing chemotherapy, participants diagnosed with locally advanced/metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy, participants diagnosed with extensive-stage small cell lung cancer (ES-SCLC), participants diagnosed with metastatic NSCLC previously untreated,and participants diagnosed with locally unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with locally advanced or metastatic Urothelial Cancer previously treated with platinum-containing chemotherapy. Enrollment is closed.
Drug: Atezolizumab
Participants diagnosed with Locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after prior chemotherapy. Participants with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumor mutations should also have received targeted therapy. Enrollment closed.
Drug: Atezolizumab
EMA: Participants diagnosed with locally advanced/metastatic non-squamous NSCLC not previously treated. Participants with EGFR-activating mutations or ALK-positive tumor mutations should have received at least one line of targeted therapy. FDA: for the treatment of adult participants with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Participants with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ. Enrollment is closed.
Drug: Atezolizumab
Participants diagnosed with extensive stage (ES) small cell lung cancer (SCLC) not previously treated. Enrollment is closed.
Drug: Atezolizumab
Participants diagnosed with metastatic Non-Small Cell Lung cancer with high PD-L1 expression, previously untreated.
Drug: Atezolizumab
Participants diagnosed with unresectable locally advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
Drug: Atezolizumab
Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
Also known as: Tecentriq
Overall Survival (OS)
Time from index date until date of death from any cause. Index date is the date of administration of the first ever dose of atezolizumab for each patient.
Time frame: Index date up to approximately 6 years
OS at 2 Years
Percentage of participants alive 2 years after initiation of atezolizumab treatment.
Time frame: After index date up to 2 years
Time to Loss of Clinical Benefit (TTLCB)
Time from the index date to loss of clinical benefit as assessed by the treating physician.
Time frame: Index date up to approximately 6 years
Progression Free Survival (PFS)
Time from index date to death or disease progression (PD).
Time frame: Index date up to approximately 6 years
Objective Response Rate (ORR)
Percentage of participants who have a best overall response (BOR) of Complete Response (CR) or Partial Response (PR). BOR for each participant is the best response achieved after the index date prior to initiation of any subsequent treatment.
Time frame: After index date up to approximately 6 years
Time to Response
Time from index date to first objective tumor response, CR or PR.
Time frame: Index date up to approximately 6 years
Duration of Response (DoR)
Time from first documentation of CR or PR (whichever occurs first) after index until death or PD.
Time frame: Index date up to approximately 6 years
Disease Control Rate (DCR)
Percentage of participants who have achieved CR, PR and stable disease at least 12 weeks after the index date.
Time frame: From 12 weeks after index date up to approximately 6 years
Duration of DCR
Time from first documentation of CR, PR or stable disease (whichever occurs first) after index until death or PD.
Time frame: After index date up to approximately 6 years
EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Score
EQ-5D-5L during and after atezolizumab treatment will be used to assess HRQoL. Scale is from 1-5 (no problems, slight problems, moderate problems, severe problems and extreme problems).
Time frame: Index date or after ICF signature, & approx. at 6, 12, and 24 weeks of treatment; then at approx. 3 months, 6 months, 12 months, & every 12 months thereafter until end of study (study planned duration up to approximately 6 years)
Number of Paricipants with Disease Stage TNM and IUCC
Time frame: At index date (Index date is the date of administration of the first ever dose of atezolizumab for each patient.)
Number of Participants at Each Level of Karnofsky or ECOG Performance Status
Time frame: At index date (Index date is the date of administration of the first ever dose of atezolizumab for each patient.
Total Number of Infusions of Atezolizuamb
Time frame: Treatment period until discontinuation (up to approximately 6 years)
Duration of Treatment With Atezolizumab
Time frame: Index date until date of treatment discontinuation (up to approximately 6 years)
Time to initiation of the first subsequent cancer-related therapy
Time frame: Up to approximately 6 years
Percentage of Participants with Adverse Events
Time frame: Up to approximately 6 years
Number of Lines of Prior and Subsequent Cancer-Related Therapies
Time frame: Up to approximately 6 years
Showing the first 100 of 257 sites across 30 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Transitional Cell →